• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

端锚聚合酶作为药物靶点。

Tankyrases as drug targets.

机构信息

Biocenter Oulu and Department of Biochemistry, University of Oulu, Oulu, Finland.

出版信息

FEBS J. 2013 Aug;280(15):3576-93. doi: 10.1111/febs.12320. Epub 2013 Jun 18.

DOI:10.1111/febs.12320
PMID:23648170
Abstract

Tankyrase 1 and tankyrase 2 are poly(ADP-ribosyl)ases that are distinguishable from other members of the enzyme family by the structural features of the catalytic domain, and the presence of a sterile α-motif multimerization domain and an ankyrin repeat protein-interaction domain. Tankyrases are implicated in a multitude of cellular functions, including telomere homeostasis, mitotic spindle formation, vesicle transport linked to glucose metabolism, Wnt-β-catenin signaling, and viral replication. In these processes, tankyrases interact with target proteins, catalyze poly(ADP-ribosyl)ation, and regulate protein interactions and stability. The proposed roles of tankyrases in disease-relevant cellular processes have made them attractive drug targets. Recently, several inhibitors have been identified. The selectivity and potency of these small molecules can be rationalized by how they fit within the NAD(+)-binding groove of the catalytic domain. Some molecules bind to the nicotinamide subsite, such as generic diphtheria toxin-like ADP-ribosyltransferase inhibitors, whereas others bind to a distinct adenosine subsite that diverges from other diphtheria toxin-like ADP-ribosyltransferases and confers specificity. A highly potent dual-site inhibitor is also available. Within the last few years, tankyrase inhibitors have proved to be useful chemical probes and potential lead compounds, especially for specific cancers.

摘要

Tankyrase 1 和 tankyrase 2 是多聚(ADP-核糖)酶,其催化结构域的结构特征以及无活性α基元多聚化结构域和锚蛋白重复蛋白相互作用结构域的存在,使它们与酶家族的其他成员区分开来。Tankyrases 参与多种细胞功能,包括端粒稳态、有丝分裂纺锤体形成、与葡萄糖代谢相关的囊泡运输、Wnt-β-catenin 信号传导和病毒复制。在这些过程中,tankyrases 与靶蛋白相互作用,催化多聚(ADP-核糖)化,并调节蛋白相互作用和稳定性。tankyrases 在与疾病相关的细胞过程中的作用使它们成为有吸引力的药物靶点。最近,已经鉴定出几种抑制剂。这些小分子的选择性和效力可以通过它们在催化结构域的 NAD(+)结合槽中的拟合程度来合理化。一些分子结合到烟酰胺亚基,如通用白喉毒素样 ADP-核糖基转移酶抑制剂,而其他分子结合到一个独特的腺苷亚基,该亚基与其他白喉毒素样 ADP-核糖基转移酶不同,并赋予特异性。也有一个高度有效的双位点抑制剂。在过去几年中,tankyrase 抑制剂已被证明是有用的化学探针和潜在的先导化合物,尤其是针对特定癌症。

相似文献

1
Tankyrases as drug targets.端锚聚合酶作为药物靶点。
FEBS J. 2013 Aug;280(15):3576-93. doi: 10.1111/febs.12320. Epub 2013 Jun 18.
2
Tankyrase inhibitors as therapeutic targets for cancer.端粒酶抑制剂作为癌症的治疗靶点。
Curr Top Med Chem. 2014;14(17):1967-76. doi: 10.2174/1568026614666140929115831.
3
Tankyrases: structure, function and therapeutic implications in cancer.端粒酶:结构、功能及在癌症治疗中的意义
Curr Pharm Des. 2014;20(41):6472-88. doi: 10.2174/1381612820666140630101525.
4
Structural basis of selective inhibition of human tankyrases.人端锚聚合酶选择性抑制的结构基础。
J Med Chem. 2012 Feb 9;55(3):1360-7. doi: 10.1021/jm201510p. Epub 2012 Jan 25.
5
A role of intracellular mono-ADP-ribosylation in cancer biology.细胞内单 ADP-核糖基化在癌症生物学中的作用。
FEBS J. 2013 Aug;280(15):3551-62. doi: 10.1111/febs.12290. Epub 2013 May 10.
6
Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.强效且选择性的非平面端锚聚合酶抑制烟酰胺类似物的发现。
Bioorg Med Chem. 2015 Aug 1;23(15):4139-4149. doi: 10.1016/j.bmc.2015.06.063. Epub 2015 Jul 2.
7
Tankyrase recruitment to the lateral membrane in polarized epithelial cells: regulation by cell-cell contact and protein poly(ADP-ribosyl)ation.端锚聚合酶在极化上皮细胞侧向膜上的募集:细胞间接触和蛋白质聚(ADP - 核糖)基化的调节
Biochem J. 2006 Nov 1;399(3):415-25. doi: 10.1042/BJ20060713.
8
Tankyrase, a poly(ADP-ribose) polymerase at human telomeres.端粒酶,一种存在于人类端粒的聚(ADP-核糖)聚合酶。
Science. 1998 Nov 20;282(5393):1484-7. doi: 10.1126/science.282.5393.1484.
9
Zinc binding catalytic domain of human tankyrase 1.人端锚聚合酶1的锌结合催化结构域
J Mol Biol. 2008 May 23;379(1):136-45. doi: 10.1016/j.jmb.2008.03.058. Epub 2008 Apr 3.
10
Tankyrase polymerization is controlled by its sterile alpha motif and poly(ADP-ribose) polymerase domains.端锚聚合酶的聚合作用由其无活性α基序和聚(ADP-核糖)聚合酶结构域控制。
Mol Cell Biol. 2004 Nov;24(22):9802-12. doi: 10.1128/MCB.24.22.9802-9812.2004.

引用本文的文献

1
The post-translational modification of NuMA in cancer cells is a new target for cancer eradication.癌细胞中核有丝分裂器蛋白(NuMA)的翻译后修饰是根除癌症的新靶点。
Cell Death Dis. 2025 Jul 18;16(1):536. doi: 10.1038/s41419-025-07868-7.
2
Liquid‒liquid phase separation and poly(ADP‒ribosyl)ation in the context of ultraviolet radiation-induced stress in mammalian cells.哺乳动物细胞紫外线辐射诱导应激背景下的液-液相分离与聚(ADP-核糖)化
Biophys Rev. 2025 Mar 11;17(2):499-510. doi: 10.1007/s12551-025-01294-x. eCollection 2025 Apr.
3
Deconstruction of Dual-Site Tankyrase Inhibitors Provides Insights into Binding Energetics and Suggests Critical Hotspots for Ligand Optimization.
双位点端锚聚合酶抑制剂的解构为结合能提供了见解,并为配体优化指明了关键热点。
J Med Chem. 2025 Apr 10;68(7):7263-7279. doi: 10.1021/acs.jmedchem.4c02845. Epub 2025 Mar 25.
4
Tankyrase inhibition promotes endocrine commitment of hPSC-derived pancreatic progenitors.端锚聚合酶抑制促进人多能干细胞来源的胰腺祖细胞的内分泌分化。
Nat Commun. 2024 Oct 9;15(1):8754. doi: 10.1038/s41467-024-53068-w.
5
A small molecule compound 759 inhibits the wnt/beta-catenin signaling pathway via increasing the Axin protein stability.小分子化合物 759 通过增加 Axin 蛋白稳定性来抑制 wnt/β- 连环蛋白信号通路。
Med Oncol. 2024 May 11;41(6):147. doi: 10.1007/s12032-024-02314-8.
6
Inhibitory Effect of a Tankyrase Inhibitor on Mechanical Stress-Induced Protease Expression in Human Articular Chondrocytes.基质金属蛋白酶诱导型蛋白酶抑制剂对机械压力诱导的人关节软骨细胞蛋白酶表达的抑制作用。
Int J Mol Sci. 2024 Jan 24;25(3):1443. doi: 10.3390/ijms25031443.
7
A novel TNKS/USP25 inhibitor blocks the Wnt pathway to overcome multi-drug resistance in TNKS-overexpressing colorectal cancer.一种新型TNKS/USP25抑制剂可阻断Wnt信号通路,从而克服TNKS过表达的结直肠癌中的多药耐药性。
Acta Pharm Sin B. 2024 Jan;14(1):207-222. doi: 10.1016/j.apsb.2023.10.013. Epub 2023 Oct 27.
8
Tankyrase: a promising therapeutic target with pleiotropic action.端锚聚合酶:一种具有多效性作用的有前景的治疗靶点。
Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396(12):3363-3374. doi: 10.1007/s00210-023-02576-5. Epub 2023 Jun 20.
9
[1,2,4]Triazolo[3,4-]benzothiazole Scaffold as Versatile Nicotinamide Mimic Allowing Nanomolar Inhibition of Different PARP Enzymes.三唑并[3,4-b]噻唑作为多功能烟酰胺类似物骨架,可实现对不同 PARP 酶的纳摩尔抑制作用。
J Med Chem. 2023 Jan 26;66(2):1301-1320. doi: 10.1021/acs.jmedchem.2c01460. Epub 2023 Jan 4.
10
Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy.揭开 5-甲基-5-[4-(4-氧代-3H-喹唑啉-2-基)苯基]咪唑烷-2,4-二酮在双重靶向 Tankyrase 1 和 2 中的作用结构机制:癌症治疗的新途径。
Cell Biochem Biophys. 2022 Sep;80(3):505-518. doi: 10.1007/s12013-022-01076-2. Epub 2022 May 30.